Hypergammaglobulinemic purpura associated with Sjögren's syndrome and chronic C type hepatitis.
Although hypergammaglobulinemic purpura usually occurs secondarily on the lower legs in several disorders, purpura has also recently been reported to be associated with chronic C type hepatitis (HCV). To define the differences in the clinical, histological and laboratory findings and the prognosis of hypergammaglobulinemic purpura associated with those two disorders, we examined ten patients with hypergammaglobulinemic purpura, 6 patients with hypergammaglobulinemic purpura associated with Sjögren's syndrome (SjS) and 4 patients with hypergammaglobulinemic purpura with chronic C type hepatitis. Five of 6 patients with SjS were female. Attacks of purpura occurred in the pretibial area in all cases. Triggering factors included long walks and prolonged standing. The mean duration of attacks was 6.4 days. No systemic manifestations were associated. Anti-Ro/SS-A and anti-La/SS-B antibodies were expressed in one case. Spontaneous regression was noted in all cases; however, recurrence was noted in one. On the other hand, all the 4 patients with hypergammaglobulinemic purpura associated with HCV were men. Purpura was indurated in a few cases. Involved sites included the knee, forearm, abdomen and thigh in addition to the lower leg. The mean duration of attacks was 12.6 days. Recurrent purpura was noted in one case. Cryoglobulin was positive in three cases. In one patient with severe recurrent purpura, attacks stopped with prednisolone 10 mg/day. Histologically, leukocytoclastic vasculitis was detected in three cases associated with SjS and two cases with HCV. In conclusion, hypergammaglobulinemic purpura associated with HCV appears to occur unilaterally with a sex predilection for men and the manifestations last longer than those associated with SjS. Severe palpable purpura was also noted in association with HCV; systemic prednisolone resulted in good control.
Yamamoto
T
T
Department of Dermatology, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.
Yokoyama
A
A
D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000974:Antibodies, Antinuclear / Q000032:analysis; D003450:Cryoglobulins / Q000032:analysis; D005260:Female; D006526:Hepatitis C / Q000150:complications*; D006521:Hepatitis, Chronic / Q000150:complications*; D006801:Humans; D007868:Leg Dermatoses / Q000209:etiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011379:Prognosis; D011694:Purpura, Hyperglobulinemic / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D012008:Recurrence; D012075:Remission, Spontaneous; D012737:Sex Factors; D012859:Sjogren's Syndrome / Q000150:complications*; D013997:Time Factors; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000209:etiology / Q000473:pathology; D016138:Walking; D016474:Weight-Bearing
D000893:Anti-Inflammatory Agents; D000974:Antibodies, Antinuclear; D003450:Cryoglobulins; C035356:SS-A antibodies; C035357:SS-B antibodies; D011239:Prednisolone